FOR LOW RISK
AORTIC STENOSIS PATIENTS
SAFE & EFFECTIVE
As demonstrated by all-cause mortality or disabling stroke, noninferior to SAVR at 24 months2
Evolut™ TAVR is the only TAVR device to demonstrate hemodynamic superiority in a low-risk clinical trial vs. SAVR1
EVOLUT TAVR SUPERIOR TO SAVR
in self-reported KCCQ measures at 30 days1
58% SHORTER HOSPITAL STAY
with TAVR procedures vs. SAVR procedures2
LOWER RATES OF REHOSPITALIZATION
with Evolut TAVR vs. SAVR2
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.
Reardon MJ. The Evolut Low Risk Trial. Presented at ACC 2019; New Orleans, LA.